Arcadia Biosciences (RKDA) Announces Leadership Transition
Arcadia Biosciences (Nasdaq: RKDA) has announced a significant leadership change. Effective July 5, 2024, Stan Jacot has stepped down as CEO, with Thomas J. Schaefer, formerly the CFO, taking over the role. Mark Kawakami, the current Vice President of Finance, will succeed Schaefer as CFO.
Stan Jacot's tenure saw expansions in Arcadia's product lines, including the GoodWheat brand's entry into three categories and its sale to Above Food, alongside the monetization of wheat IP and a revamp of Zola coconut water. Schaefer, with over 20 years of experience in corporate finance and consumer products, has contributed significantly to the company's transition from agricultural research to consumer goods.
Chairman Kevin Comcowich expressed confidence in Schaefer's ability to lead the company towards profitability, highlighting his role in developing Project Greenfield. Kawakami, with over 20 years of finance experience, is expected to bring valuable expertise to his new role as CFO.
- Thomas J. Schaefer's appointment as CEO brings over 20 years of corporate finance and consumer products experience.
- Mark Kawakami's promotion to CFO ensures continuity with his extensive background in finance and accounting.
- The leadership transition aligns with Arcadia's strategic plan, Project Greenfield, aimed at profitability.
- Leadership changes might bring uncertainties and potential instability in the short term.
- Departure of Stan Jacot, who led significant product expansions and business divestitures.
-- CEO Stan Jacot replaced by CFO Thomas J. Schaefer --
“On behalf of Arcadia, I would like to thank Stan for his many contributions to the company,” said Board of Directors Chairman Kevin Comcowich. “Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to Above Food, monetized a portion of our wheat IP, revamped Zola coconut water and divested or exited several unprofitable businesses. We wish him all the best in the next phase of his career.”
Schaefer is an accomplished executive with more than 20 years of experience in investments and corporate finance. He began his career as an equity research analyst and later joined a Fortune 500 company where he helped lead several acquisitions and divestitures. In 2013, Schaefer moved into consumer products where he led teams, developed long-range strategies and helped launch new products across a variety of industries including vitamins and apparel. He later served as director of finance at Flavor Producers, a portfolio company owned by private equity firm GTCR that specialized in beverages and snacks, before joining Arcadia in 2020.
Schaefer earned a bachelor of business administration in economics and finance from McKendree University and a master of business administration (MBA) from the Marshall School of Business at the University of
“T.J. has played a significant role in the company’s transition from ag research to consumer goods, and he was instrumental in the development of Project Greenfield, the company’s strategic plan to unlock the company’s potential and provide a path to profitability,” said Comcowich. “We welcome his leadership as we continue to expand the footprint of Zola coconut water, explore strategic opportunities, monetize our IP and create value for our shareholders.”
Schaefer’s successor as chief financial officer, Mark Kawakami, joined Arcadia in 2021, and he has held several key positions, most recently as the vice president of finance. Kawakami brings more than 20 years of finance and accounting experience to the role, with a background in industries such as convenience and retail grocery, food manufacturing, consumer packaged goods and financial services. He is a graduate of the University of
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating crops to provide high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make everybody feel good. For more information, visit arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the success of the company’s long-term strategy, the growth of the company’s Zola business and the monetization of the company’s intellectual property. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the risks set forth in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2023 and other filings Arcadia makes with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709010359/en/
Sue Wandell
ir@arcadiabio.com
Source: Arcadia Biosciences, Inc.
FAQ
When did Thomas J. Schaefer become CEO of Arcadia Biosciences?
What experience does Thomas J. Schaefer bring to his role as CEO of Arcadia Biosciences?
Who is the new CFO of Arcadia Biosciences after the leadership change?
What impact did Stan Jacot have during his tenure as CEO of Arcadia Biosciences?
What is Project Greenfield in relation to Arcadia Biosciences?
